source
- Daraxonrasib uniquely targets active KRAS in pancreatic cancer, says MD Anderson expertDr Shubham Pant, a professor in the Department of Gastrointestinal Medical Oncology at MD Anderson Cancer Center, explained the mechanism of daraxonrasib in a recent commentary. The oral, potent R…
- Sanofi requests removal of teplizumab from FDA fast-track voucher program after director disputeSanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…